国药集团 Sinopharm
中国医药集团是由国务院国资委直接管理的中国最大的医药健康产业集团，以预防治疗和诊断护理等健康相关产品的分销、零售、研发及生产为主业。中国医药集团成立于1998年，由中国医药（集团）公司、中国医药工业公司、中国医药对外贸易总公司、中国医疗器械工业公司4家企业联合组建而成。2003年中国药材集团进入集团、2009年集团与中国生物技术集团公司联合重组、2010年上海医药工业研究院、中国出国人员服务总公司进入集团。目前集团旗下拥有十家全资或控股子公司，国药控股一家H股上市公司及国药股份、天坛生物、现代制药、一致药业四家A股上市公司。中国医药集团2011年实现营业收入超过1200亿元。

中国医药集团正在全力推进集团五大平台——现代物流分销一体化平台、产学研一体化科技创新平台、国际经营一体化平台、医疗健康产业平台、高效管控与融合协同一体化平台的全面建设，依托集团五大平台协同运作，促进集团十一个核心业务——医药现代物流分销、医药零售、生物制品、化学制药、现代中药、诊断试剂与化学试剂、科学仪器与医疗器械、医药科研与工程设计、医药国际经营与海外实业、医药会展与传媒、医疗健康产业的全面发展，构成了一个完整的中央企业医药健康产业平台，实现了规模效益，推动业绩高速增长。2003年至2011年中国医药集团营业收入年平均增幅33%，利润总额年平均增幅44%，总资产年平均增幅35%。目前已拥有覆盖全国31个省、自区、直辖市的医药流通配送网络和与国际水平接轨的30个配送中心及生产基地。中国医药集团在国内拥有一流的医药及疫苗、血液制品生产企业、高水平的科研设计院所、覆盖全国的营销络、大规模的药材种植基地及全国第一的医药会展，产业链完整。从1980年开始先后与国外的著名跨国医药公司合作，建立了中国大冢制药有限公司、无锡华瑞制药有限公司等20家中合资医药生产企业，与美国、日本、法国、英国、德国、意大利、韩国等多个国家开展了国际技术合作项目，并与世界上100多个国家和地区建立了贸易和合作关系，有力地促进了我国医药生产经营和医药行业管理水平的提高。

中国医药集团以“关爱生命、呵护健康”为企业理念，其所属企业承担着全国抢险救灾药品、生物技术产品、中药材、医疗器械的中央储备、调拨和供应任务，在1976年唐山大地震、1998年抗洪抢险、2003年抗击非典的战斗中；在2008年汶川抗震救灾、2009年防控甲型H1N1流感疫情、2010年玉树和舟曲抗震救灾的现场；在2008年奥运会、2009年国庆阅兵和2010年上海世博会等重大事件医药物资储备与应急供应，以及2010年国家麻疹疫苗强化免疫活动中，都能看到国药人紧张工作的身影，为保障人民的生命健康和社会稳定发挥了重要作用。同时, 集团研发生产的疫苗出口到印度、泰国、韩国、尼泊尔、斯里兰卡等国，为当地民众健康做出了积极贡献。

中国医药集团总公司是中国化学制药工业协会、中国麻醉药品协会、中国医药商业协会、中国医药科研开发促进会、中国医疗器械行业协会、中国中药协会、中国药文化研究会等行业组织的会长或理事长单位，还是全国药品交易会等重要会展的主办和支持单位。

中国医药集团的发展目标是，“十二五”期间，建成涵盖医药行业全产业链的，具有行业带动力和国际竞争力的大型医药健康产业集团，成为进入世界500强的第一家中国医药健康企业。

China National Pharmaceutical Group Corporation, (Sinopharm) is the largest medical and healthcare group in China which is directly managed by State-owned Assets Supervision and Administration Commission of the State Council (SASAC), with the core businesses of distribution, logistics, retail, scientific research and manufacture of healthcare related products. Associated built on the basis of the four state-owned companies: China National Pharmaceutical (Group) Corporation, China National Pharmaceutical Industry Corporation, China National Pharmaceutical Foreign Trade Corporation and China National Medical Equipment Industry Corporation, Sinopharm was established in 1998. In 2003, China National Group Corporation of Traditional & Herbal Medicine joined Sinopharm. In 2009, Sinophrm restructured with China National Bio-tech Group (CNBG). As well as in 2010, Shanghai Institute of Pharmaceutical Industry (SIPI) and China National Service Corporation for Chinese Personnel Working Abroad (CNSC) joined Sinopharm. So far, Sinopharm owns 10 wholly owned or holding subsidiaries, and 5 listed companies including Sinopharm Group Co., Ltd. (01099.HK), China National Medicines Co., Ltd. (600511.SH), Beijing Tiantan Biological Products Co., Ltd. (600161.SH), Shyndec Pharmaceutical Co., Ltd. (600420.SH) and Shenzhen Accord Pharmaceutical Co., Ltd. (200028.SZ). The sales revenue of Sinopharm exceeded RMB 160 billion in 2012. It is the only Chinese pharmaceutical company whose sales revenue exceeds RMB 100 billion.
With all-out efforts, Sinopharm is promoting the overall construction of five major platforms – the modern integrated distribution and logistics platform, the integrated manufacturing and R&D platform for scientific and technological innovation, the integrated globally operational platform, the health care industry platform and the highly efficient control and integration services platform, to comprehensively advance the joint development of the eleven core business sectors of modern pharmaceutical logistics and distribution; medicine retail; biological products; chemical pharmaceuticals; modern TCM; diagnosis reagents and chemical reagents; scientific instruments and medical equipments; medical scientific research and engineering design; pharmaceutical international trade and overseas industry, pharmaceutical exhibitions and media; health care industry. So far, Sinopharm has formed an immense and complete pharmaceutical and healthcare industrial platform, realized the scale effect and promote a high-speed growth. Since Year 2003 to Year 2011, the annual average growth rate of revenue was 33%, the annual average growth rate of gross profit was 44% and the annual average growth rate of total assets was 35%. Besides the largest pharmaceutical and medical distribution network covering 31 provinces, autonomous regions and municipalities and 30 international standard distribution centers and production bases, Sinopharm also owns the first-class manufacturers for medicines, vaccines, blood products, high-level scientific and technological institutes, massive planting bases for medicinal herbs and most of domestic medicine and health care related professional exhibition brands in China. Since 1980s, Sinopharm has cooperated with renowned multinationals, established dozens of Sino-foreign pharmaceutical joint ventures, e.g. China Otsuka Pharmaceutical Co., Ltd. (COP) and Sino-Swed Pharmaceutical Co., Ltd. (SSPC), jointly conducted international technologic programs with companies from the U.S.A., Japan, France, UK., Germany, Italy and Korea, built up collaborative relationship with the clients from over 100 countries and regions. The broad international cooperation have energetically promoted the operation and management ability of the industry in China.
Adhering to the corporate conception of 'Caring for life, attending to health', Sinopharm and its subsidiaries have always undertaken the responsibility of central reserve, allocation and supply of medicines and health care related products against emergencies disasters and epidemics. Sinopharm staff could be found at the emergency sites of various catastrophic disasters and significant events, e.g. Tangshan Earthquake in 1976, fighting against floods in 1998, prevention and treatment of SARS in 2003, earthquake relief of Wenchuan Earthquake in 2008, control of influenza A H1N1 in 2009, earthquake relief effort of Yushu Earthquake and Zhouqu Mudslide in 2010, Beijing Olympic Games in 2008, National Day parade in 2009, Shanghai Expo 2010 and national measles supplementary immunization in 2010. Sinopharm has been playing an important role in nationwide preventing and curing diseases, securing public health and promoting the development of the industry. Meanwhile, Sinopharm has exported vaccines to India, Thailand, South Korea, Nepal, Sri Lanka, etc., which made great contribution to local public health.
Sinopharm is taking leading positions of 9 medical industry associations, e.g. China Pharmaceutical Industry Association (CPIA), China National Narcotic Drugs Association (CNNDA), China Association of Pharmaceutical Commerce (CAPC), China Pharmaceutical Industry Research and Development Association (Sino-PhIRDA), China Association For Medical Devices Industry (CAMDI), China Association of Traditional Chinese Medicine (CATCM), and China Pharmaceutical Culture Society, etc. as well as the organizer of many pharmaceutical and healthcare exhibitions and conferences, e.g. Phram China.
Sinopharm is aiming to be an international pharmaceutical and healthcare group which covering the whole industrial chain and can give strong impetus to the industry as well as the first Chinese pharmaceutical company of the Global Top 500 Corporations during the period of "the 12th Five-Year-Plan".